Ferric derisomaltose versus usual care in patients with heart failure, reduced ejection fraction, and iron deficiency: a short-term UK cost-utility analysis based on the IRONMAN RCT

被引：0
|
作者：
Pollock, R. [1 ]
Kalra, P. R. [2 ]
Mcmurray, J. J., V [3 ]
Graham, F. J. [4 ]
Pellicori, P. [5 ]
Cleland, J. G. F. [5 ]
Ford, I [4 ]
机构：
[1] Covalence Res Ltd, Harpenden, England
[2] Portsmouth Hosp Univ NHS Trust, Dept Cardiol, Portsmouth, England
[3] BHF Glasgow Cardiovasc Res Ctr, Sch Cardiovasc & Metab Hlth, Glasgow, Scotland
[4] Robertson Ctr Biostat, Glasgow, Scotland
[5] Univ Glasgow, Sch Cardiovasc & Metab Hlth, Glasgow, Scotland
来源：
EUROPEAN HEART JOURNAL | 2024年 / 45卷
关键词：
D O I：
10.1093/eurheartj/ehae666.852
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Patients with Iron Deficiency Anemia in China
    Zhang, Fengkui
    Shen, Aizong
    Ahmed, Waqas
    Pollock, Richard F.
    ADVANCES IN THERAPY, 2024, 41 (11) : 4191 - 4204
  • [2] A COST-UTILITY ANALYSIS OF FERRIC DERISOMALTOSE VERSUS FERRIC CARBOXYMALTOSE IN PATIENTS WITH IRON DEFICIENCY ANEMIA IN CHINA
    Zhang, F.
    Shen, A.
    Ahmed, W.
    Pollock, R.
    VALUE IN HEALTH, 2023, 26 (12) : S102 - S103
  • [3] Risk of infection with ferric derisomaltose compared to standard of care in patients with heart failure and iron deficiency in the uk: a prespecified analysis of the ironman trial
    Foley, Paul
    Kalra, Paul
    Lane, Rebecca
    Petrie, Mark
    Cowburn, Peter
    Thomson, Elizabeth
    Critoph, Christopher
    Ray, Robin
    Robertson, Michele
    Clark, Andrew
    Ford, Ian
    Clelland, John G. F.
    Squire, Iain
    HEART, 2023, 109 : A156 - A156
  • [4] A UK COST-UTILITY ANALYSIS OF FERRIC CARBOXYMALTOSE VERSUS FERRIC DERISOMALTOSE IN PATIENTS WITH IRON DEFICIENCY ANEMIA AND INFLAMMATORY BOWEL DISEASE: INCORPORATION OF FRACTURE DATA
    Zoller, H.
    Pammer, L. M.
    Nottmeier, M.
    Poehlmann, J.
    Pollock, R. F.
    VALUE IN HEALTH, 2024, 27 (06) : S69 - S70
  • [5] Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England
    Iqbal, Tariq H.
    Kennedy, Nicholas
    Dhar, Anjan
    Ahmed, Waqas
    Pollock, Richard F.
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 392 - 403
  • [6] A cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anaemia in Finland
    Metsarinne, K.
    Saavuori, N.
    Ahmed, W.
    Pollock-Wilkins, R.
    Salminen, K.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1885 - I1886
  • [7] A COST-UTILITY ANALYSIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND IRON DEFICIENCY ANEMIA IN THE NETHERLANDS: REDUCED HYPOPHOSPHATEMIA AND FRACTURE INCIDENCE WITH FERRIC DERISOMALTOSE VERSUS FERRIC
    Oron, U.
    Koek, G.
    Fijn, R.
    Pollock, R.
    VALUE IN HEALTH, 2024, 27 (12) : S116 - S116
  • [8] A SWEDISH COST-UTILITY ANALYSIS OF FERRIC DERISOMALTOSE VERSUS FERRIC CARBOXYMALTOSE IN THE TREATMENT OF IRON DEFICIENCY ANEMIA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Lindgren, S.
    Pollock, R.
    VALUE IN HEALTH, 2023, 26 (12) : S162 - S162
  • [9] COST-UTILITY ANALYSIS OF FERRIC DERISOMALTOSE VERSUS FERRIC CARBOXYMALTOSE IN TREATING IRON DEFICIENCY ANEMIA IN NORWEGIAN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Detlie, T. E.
    Karlsen, L. N.
    Pollock, R.
    VALUE IN HEALTH, 2023, 26 (12) : S131 - S131
  • [10] Infection risk with ferric derisomaltose compared to standard of care in patients with heart failure and iron deficiency: a prespecified analysis of the IRONMAN trial
    Kalra, P.
    Cleland, J. G. F.
    Foley, P. W. X.
    Petrie, M.
    Thomson, E.
    Kalra, P. A.
    Squire, I. B.
    Graham, F.
    Pellicori, P.
    Macdougall, I.
    Robertson, M.
    Clark, A.
    Lane, R. E.
    Ahmed, F. Z.
    Ford, I.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 : 259 - 259
12345